Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA20
Go back to Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA20| Beam Inc. (NASDAQ: BEAM) | Delayed: 35.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.53 | 52 Week High | $83.60 | |||
| Open | $35.53 | 52 Week Low | $82.96 | |||
| Day High | $35.53 | P/E | 15.86 | |||
| Day Low | $35.53 | EPS | $2.24 | |||
| Volume | 73,174 | |||||
